CN1CCN(C2C=CC(NC3C4N(N=CN=4)C(C4C=C(C(N)=O)SC=4)=CN=3)=CC=2)CC1.[C:32]([O:36][C:37]([N:39]1[CH2:44][CH2:43][N:42]([C:45]2[CH:50]=[CH:49][C:48]([NH:51][C:52]3[C:53]4[N:54]([N:59]=[CH:60][N:61]=4)[C:55](Br)=[CH:56][N:57]=3)=[CH:47][CH:46]=2)[C:41](=[O:62])[CH2:40]1)=[O:38])([CH3:35])([CH3:34])[CH3:33].CC1(C)C(C)(C)OB([C:71]2[CH:72]=[C:73]3[C:77](=[CH:78][CH:79]=2)[C:76](=[O:80])[NH:75][CH2:74]3)O1.C([O-])([O-])=O.[Na+].[Na+]>[Cl-].[Na+].O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.C1(C)C=CC=CC=1.O1CCOCC1>[C:32]([O:36][C:37]([N:39]1[CH2:44][CH2:43][N:42]([C:45]2[CH:50]=[CH:49][C:48]([NH:51][C:52]3[C:53]4[N:54]([N:59]=[CH:60][N:61]=4)[C:55]([C:71]4[CH:72]=[C:73]5[C:77](=[CH:78][CH:79]=4)[C:76](=[O:80])[NH:75][CH2:74]5)=[CH:56][N:57]=3)=[CH:47][CH:46]=2)[C:41](=[O:62])[CH2:40]1)=[O:38])([CH3:35])([CH3:34])[CH3:33]This compound may be prepared using methods as described for Compound 6, step 4, using 4-[4-(5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamino)-phenyl]-3-oxo-piperazine-1-carboxylic acid tert-butyl ester (115 mg, 0.24 mmol), 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-isoindol-1-one (92 mg, 0.35 mmol), and Pd(PPh3)4 (83 mg, 0.072 mmol) in 1.5M Na2CO3 (aq) (1.3 mL, 1.92 mmol), and dioxane (2.5 mL). The reaction mixture is diluted with brine then toluene is added and a precipitate is formed and collected by filtration. The resultant solid is dissolved in DCM and filtered through a silica cartridge to afford the title compound as a yellow solid (60 mg, 47%).